Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Company

Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS
CompanyDrug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Cutia Therapeutic's CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study
CompanyDrug

Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System
CompanyDeals

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System

NMPA Approves Shenzhen Mindray's Innovative Dual-Mode Ultrasound Diagnostic System
CompanyMedical Device

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

NMPA Approves Hangzhou Ruidi Biotechnology's Steep Pulse Therapy Equipment for Tumor Treatment
CompanyMedical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment

CDE Expands Care Plan with Approvals for Ractigen's RAG-17 and Vitalgen's VGR-R01
CompanyDrug

CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01

NMPA Drafts Medical Representative Management Measures, Seeks Public Input
Policy / Regulatory

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai
CompanyDeals

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A
CompanyDrug

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
CompanyDeals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

Sichuan Biokin Pharmaceutical's BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
CompanyDrug

Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials